BioSpace News Archive

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, announced clearance by the U.S. Food and Drug Administration (FDA) for the Company’s 510(k) premarket notification submission to market Pure Impact™ utilizing PlyoPulse™ EMS (“electromagnetic stimulation”) technology in the United States.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 2:15 p.m. PT in San Francisco.

Salarius Pharmaceuticals, Inc. announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center is now listed as active and recruiting on clinical trials.gov – trial NCT04734990.

TC BioPharm today announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway.

Turn Biotechnologies announced the expansion of its eTurna™ delivery platform that is expected to overcome the greatest challenge to breakthrough therapies: The safe and efficient targeting of specific organs and cells.

BioPhotas, Inc., the market leader in therapeutic LED Light Therapy devices announced that its Board of Directors has named Curtis A. Cluff as the Company’s CEO.

Orca Bio today announced that Ivan Dimov, Ph.D., Orca Bio’s co-founder and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Medable Inc. today announced that Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

TRex Bio, Inc. today announced that Johnson & Johnson Innovative Medicine has exercised the first of its options for an exclusive license to develop and commercialize a program arising out of the parties’ collaboration.

NorthStar Medical Radioisotopes, LLC and Curadh MTR Inc. announced a long-term strategic collaboration to develop and produce novel radiopharmaceuticals for the diagnosis and treatment of solid tumor cancers.